FF305 表格類別： 股票 狀態： 新提交 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年7月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 ...

Core Viewpoint - The Chinese innovative drug industry is experiencing significant growth in the first half of 2025, driven by policy benefits and international breakthroughs, with leading companies achieving explosive growth due to technological barriers and commercialization capabilities [1]. Company Performance Summaries - **Shuanglu Pharmaceutical**: Expected net profit for H1 2025 is between 100 million and 135 million RMB, a year-on-year increase of 237.95% to 356.24% from 29.59 million RMB in the same period last year, primarily benefiting from financial asset returns and breakthroughs in innovative drug pipelines [3][4]. - **Sino Biopharmaceutical**: Anticipated net profit ranges from 77.03 million to 94.14 million RMB, reflecting a year-on-year increase of 253.54% to 332.10%, driven by strong performance in peptide raw material exports [5][7]. - **Microchip Biotech**: Expected net profit of approximately 30.06 million RMB, representing a 173% increase, attributed to the inclusion of its core product (Sida Benamine) in medical insurance and optimized sales strategies [8][10]. - **Buchang Pharmaceutical**: Projected net profit between 488 million and 708 million RMB, a year-on-year increase of 110.88% to 205.94%, due to increased sales scale and reduced production costs [11][13]. - **Ganli Pharmaceutical**: Expected net profit of 600 million to 640 million RMB, a year-on-year increase of 100.73% to 114.12%, driven by significant revenue growth and refined expense management [15][16]. - **Shanghai Pharmaceuticals**: Anticipated net profit of 4.45 billion RMB, an increase of approximately 52% from the previous year, following the acquisition of a 10% stake in Shanghai Hengrui Medicine [17][18]. - **Liaoning Chengda**: Expected net profit between 689 million and 735 million RMB, a year-on-year increase of 50% to 60%, supported by a dual-driven strategy of healthcare and financial investment [19][21]. - **WuXi AppTec**: Projected net profit of approximately 6.3 billion RMB, a year-on-year increase of about 44.43%, driven by optimized CRDMO business models and significant non-operating gains from stock sales [23][25]. - **Notai Biopharmaceutical**: Expected net profit between 300 million and 330 million RMB, a year-on-year increase of 32.06% to 45.27%, attributed to sales growth in peptide raw materials [27][29]. - **I-Wu Biotech**: Anticipated net profit between 170 million and 180 million RMB, reflecting a year-on-year increase of 13.92% to 23.97%, focusing on allergy disease treatment products [30][31]. Industry Trends - The performance divergence in the innovative drug industry in 2025 indicates a shift from "scale competition" to "technological competition," with companies possessing genuine innovation capabilities and international layouts expected to lead, while those relying on capital operations or policy arbitrage face growth challenges [32].

Group 1 - The Hong Kong pharmaceutical outsourcing sector stocks experienced a collective surge, indicating positive market sentiment [1] - Kingsoft Biotech (01548.HK) rose over 6%, reflecting strong investor interest [1] - Kelaiying (06821.HK) increased by more than 5%, showcasing robust performance in the sector [1] - WuXi AppTec (02359.HK) saw a rise of over 2%, contributing to the overall strength of the industry [1] - Tigermed (03347.HK) gained more than 1%, further highlighting the upward trend in pharmaceutical outsourcing stocks [1]

AI基金富国医疗产业混合发起式A（021450）披露2025年二季报，第二季度基金利润15.75万元，加权平均基金份额本期利润0.0147元。报告期内，基金净值 增长率为1.46%，截至二季度末，基金规模为1101.36万元。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至7月21日，单位净值为1.068元。基金经理是孙笑悦，目前管理3只基金近一年均为正收益。其 中，截至7月21日，富国医药成长30股票近一年复权单位净值增长率最高，达81.88%；富国医疗产业混合发起式A最低，为8.42%。 基金管理人在二季报中表示，本基金旨在差异化深耕医疗器械和医疗服务板块，尤其是医疗器械板块。我们看好国内医疗器械产业的长期发展，虽然其短期 受到医院合规运动的影响、DRGS/DIP 等政策影响，业绩短期承压，但国内医工结合蓬勃发展、制造业和供应链的优势明显，皆有利于国内医疗器械行业的 长足发展。因此我们将继续深挖医疗器械股票标的，继续对该板块保持关注。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比较情况。图为坐标原点到区间内某时点的净值增长率在同类基金中的分位数。 截至6月27日，基金成立以来 ...

Core Points - The CSI Biopharmaceutical Theme 50 Index (CSI Pharma 50) has shown significant growth, with an increase of 8.88% over the past month, 15.61% over the past three months, and 12.91% year-to-date [1] - The index comprises 50 listed companies in the biopharmaceutical sector that exhibit high profitability, strong cash flow, and innovation capabilities, reflecting the overall performance of representative companies in this theme [1] Index Composition - The top ten weighted companies in the CSI Pharma 50 Index are: WuXi AppTec (17.54%), Hengrui Medicine (15.25%), Mindray Medical (11.6%), Aier Eye Hospital (4.96%), Kelun Pharmaceutical (3.32%), New Horizon (2.9%), Changchun High-tech (2.83%), Aimeike (2.28%), Huatai Medical (2.12%), and Baillie Gifford (2.05%) [1] - The index is evenly split between the Shenzhen Stock Exchange and the Shanghai Stock Exchange, each accounting for 50% of the holdings [1] Industry Breakdown - The industry composition of the CSI Pharma 50 Index is as follows: Chemical drugs (31.34%), Medical devices (25.53%), Pharmaceutical and biotechnology services (19.38%), Biopharmaceuticals (15.64%), Medical commerce and services (4.96%), and Traditional Chinese medicine (3.14%) [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]

Group 1 - The core point of the article highlights the performance and holdings of the ICBC Frontier Medical Stock A fund, which has a recent net value of 3.3810 yuan, reflecting a decline of 1.11% [1] - The fund has achieved a return of 12.70% over the past month, ranking 117 out of 717 in its category; a return of 29.84% over the past six months, ranking 54 out of 704; and a year-to-date return of 28.51%, ranking 62 out of 702 [1] - The top ten holdings of the fund account for a total of 59.44%, with significant positions in companies such as Heng Rui Pharmaceutical (9.51%), Kelun Pharmaceutical (9.16%), and Xin Li Tai (6.70%) [1] Group 2 - The ICBC Frontier Medical Stock A fund was established on February 3, 2016, and as of June 30, 2025, it has a total scale of 9.33 billion yuan, managed by fund manager Zhao Bei [1] - Zhao Bei holds a master's degree and has extensive experience in the investment management field, having worked in various roles since joining ICBC Credit Suisse in 2010 [2]

Core Viewpoint - Shaanxi Ruike New Materials Co., Ltd. is pursuing an IPO on the Beijing Stock Exchange, but its revenue has been declining during the reporting period from 2022 to 2024 [1][3]. Financial Performance - The total revenue for Shaanxi Ruike from 2022 to 2024 is projected to decline from 1.184 billion yuan in 2022 to 1.052 billion yuan in 2024, with net profits decreasing from 111.49 million yuan to 69.03 million yuan [2][3]. - The company's gross profit margin has shown slight improvement, increasing from 11.12% in 2022 to 12.31% in 2024 [2]. Customer Dependency - The company's major client, WuXi AppTec, has seen a significant decrease in its revenue contribution, dropping from 192 million yuan in 2022 to 40 million yuan in 2024, with its share of total revenue falling from 16.23% to 3.77% [4][7]. - Shaanxi Ruike's business model includes sales of precious metal catalysts and processing services, with the processing revenue accounting for approximately 10% of total income during the reporting period [3]. Shareholder Changes - Eight new shareholders, including four institutional investors, acquired shares in Shaanxi Ruike within 12 months prior to the IPO application, primarily through share transfers [1][8]. - The underwriter for the IPO, Guosen Securities, indirectly holds 0.73% of the company's shares through two institutional shareholders, raising questions about compliance with regulations [8][11]. Agreements and Contracts - Previous agreements involving the company's actual controllers included clauses related to share repurchase in the event of IPO failure, which have been inherited by some of the new shareholders [9][10].

7月21日，沪指上涨0.72%，深成指上涨0.86%，创业板指上涨0.87%，沪深300指数上涨0.67%。可交易 A股中，上涨的有4005只，占比74.11%，下跌的1291只。 资金面上，今日主力资金全天净流出69.45亿元。其中，创业板主力资金净流出86.67亿元；科创板主力 资金净流出17.36亿元；沪深300成份股主力资金净流出17.19亿元。 分行业来看，申万所属的一级行业中，今日上涨的有27个，涨幅居前的行业为建筑材料、建筑装饰，涨 幅为6.06%、3.79%。跌幅居前的行业为银行、综合，跌幅为0.77%、0.34%。 个股方面，全天资金净流入的个股共有2209只，净流入在1000万元以上的有888只，其中，净流入资金 超亿元的有104只，净流入资金最多的是宁德时代，今日上涨3.12%，全天资金净流入11.45亿元，其次 是卧龙电驱、C华新等，净流入资金分别为8.78亿元、8.66亿元。资金净流出超亿元的有99只，净流出 资金规模居前的个股为东方财富、四方精创、药明康德，分别净流出资金10.41亿、7.32亿元、7.23亿 元。（数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨 ...

Core Viewpoint - The Hong Kong Hang Seng Index closed up 0.68% at 24,994.14 points, reaching a new high since February 2022, with significant contributions from state-owned enterprises [1] Group 1: Market Performance - The Hang Seng Index briefly surpassed the 25,000 points mark during trading [1] - The AH premium decreased by 0.67% to 125.44, marking the lowest level since June 2020, indicating a narrowing price gap between H-shares and A-shares [2] Group 2: Stock Movements - Major state-owned enterprises led the gains in the Hang Seng Index, with China Petroleum & Chemical Corporation rising by 5.53%, China National Petroleum Corporation by 3.61%, and China Shenhua Energy Company by 2.94% [1] - Several companies related to the Yarlung Tsangpo River hydropower project saw significant stock price increases, with Huaxin Cement, Dongfang Electric, and Chongqing Iron & Steel achieving daily price limits in A-shares, while their H-shares surged by 85.63%, 65.21%, and 25.53% respectively [2] Group 3: AH Share Premiums - As of July 21, the number of AH companies with H-shares priced higher than A-shares increased to 8, with CATL showing the highest premium of 36.69% [3] - Other companies with significant premiums included Huaxin Cement (17.99%), Dongfang Electric (14.84%), and Hengrui Medicine (14.1%) [3] Group 4: Market Trends and Outlook - The AH premium has remained low for the past month, with only 3 companies previously showing H-shares priced higher than A-shares [4] - Despite challenges such as external tariff pressures and a weakening domestic growth cycle, the Hong Kong market remains active, with a daily average trading volume of 2,406 million HKD, an increase of over 80% from 2024 [4] - The influx of southbound capital has also been robust, with an average daily inflow of 61.5 million HKD, nearly double the 34.7 million HKD from 2024 [4] Group 5: IPO and Market Dynamics - The number of companies listing in Hong Kong is increasing, with 10 A-share companies converting to H-shares, raising 70% of their funds from this transition [5] - Short-term AH premiums are constrained by a "hidden floor" due to dividend tax arrangements, while long-term macro factors supporting Hong Kong's capital market remain unchanged [5]